Rashtriya Newsflash

(Albany, US) September 15, 2026 – DelveInsight’s “Gastroparesis Pipeline Insight, 2026” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Gastroparesis pipeline landscape. It covers the Gastroparesis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastroparesis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Gastroparesis Pipeline Report @ https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight

Key Takeaways from the Gastroparesis Pipeline Report

• In September 2026 – the American Gastroenterological Association (AGA) released a new clinical practice guideline for gastroparesis, providing 12 conditional recommendations for diagnosis and management and emphasizing individualized treatment because of the continuing unmet need in the disease.
• In June 2026 – Dr. Falk Pharma and Renexxion announced positive Phase IIb MOVE-IT results for naronapride in gastroparesis. Following the positive results, the companies announced plans to advance naronapride into late-stage development, making it one of the more notable recent pipeline developments in gastroparesis.
• DelveInsight’s Gastroparesis pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Gastroparesis treatment.
• The leading Gastroparesis Companies include CinDome Pharma Inc., Aclipse Therapeutics, and others.
• Promising Gastroparesis Pipeline Therapies such as Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611, and others.

Access DelveInsight’s in-depth Gastroparesis Pipeline Analysis for a closer look at promising breakthroughs @ Gastroparesis Clinical Trials and Studies

The Gastroparesis Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Gastroparesis Pipeline Report also highlights the unmet needs with respect to gastroparesis.

Gastroparesis Overview

Gastroparesis is a chronic condition characterized by delayed gastric emptying without mechanical obstruction, persisting for at least three months. It commonly presents with nausea, vomiting, bloating, early satiety, and abdominal pain, resulting from impaired gastrointestinal motor function involving the nervous system, smooth muscle, pacemaker cells, and pyloric sphincter, alongside immune alterations. Idiopathic causes are most frequent, followed by diabetic, postsurgical, and postinfectious origins, with rising incidence linked to increasing rates of diabetes, obesity, and certain medications. Symptoms often overlap with functional dyspepsia, necessitating diagnostic testing, while management primarily relies on dietary modifications due to limited efficacy and tolerance of medications.

Gastroparesis Emerging Drugs Profile

• CIN-102: CinDome Pharma, Inc.

Deudomperidone (CIN-102) is a novel chemical entity derived through deuteration and reformulation of domperidone, a widely prescribed first-line therapy for nausea, vomiting, and gastroparesis. Orally administered, it has been specifically designed to modify the pharmacokinetic profile, delivering sustained efficacy while markedly reducing cardiac risk. Clinical trials have consistently shown deudomperidone to be well tolerated, with no sponsor-assessed drug-related adverse events or clinically significant laboratory abnormalities observed. Currently, the drug is in Phase II stage of its development for the treatment of Gastroparesis.

The Gastroparesis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.
• Gastroparesis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market

Explore groundbreaking therapies and clinical trials in the Gastroparesis Pipeline @ New Gastroparesis Drugs

Gastroparesis Companies

CinDome Pharma Inc., Aclipse Therapeutics, and others.

Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Gastroparesis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies @ Gastroparesis Market Drivers and Barriers, and Future Perspectives

Scope of the Gastroparesis Pipeline Report

• Coverage- Global
• Gastroparesis Companies- CinDome Pharma Inc., Aclipse Therapeutics, and others.
• Gastroparesis Pipeline Therapies- Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611 and others.
• Gastroparesis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastroparesis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Gastroparesis drug development? @ Gastroparesis Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Gastroparesis : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastroparesis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. CIN-102: CinDome Pharma, Inc.
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. Gastroparesis Key Companies
14. Gastroparesis Key Products
15. Gastroparesis – Unmet Needs
16. Gastroparesis – Market Drivers and Barriers
17. Gastroparesis – Future Perspectives and Conclusion
18. Gastroparesis Analyst Views
19. Gastroparesis Key Companies
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gastroparesis-pipeline-insight